Affymetrix Inc.
!%Affymetrix Inc.%! of Santa Clara, Calif., has signed an agreement with Medical Prognosis Institute A/S of Horsholm, Denmark, to develop and commercialize microarray-based drug-sensitivity prediction and prognostic products for patients with cancer. The agreement grants the institute nonexclusive access to the company’s microarray technology. The institute hopes to obtain regulatory clearance and to achieve commercialization within two years.
The technology also is being used by Wellcome Trust Sanger Institute of Hinxton, UK, to catalog the structural genomic changes in nearly 800 cancer cell lines. The information will enable the institute to advance understanding of the disease and may assist with diagnoses and treatment options in the future.
LATEST NEWS
- CLEO Heads to the East Coast
Apr 29, 2024
- Laser-Based Gas Analyzer Developed to Detect Air Pollution
Apr 29, 2024
- Qubits Could be Stored in Flash-Like Memory
Apr 29, 2024
- Exail Signs LLNL Contract, Partners with Eelume
Apr 26, 2024
- Menlo Moves U.S. HQ: Week in Brief: 4/26/2024
Apr 26, 2024
- Optofluidics Platform Keys Label-, Amplification-Free Rapid Diagnostic Tool
Apr 25, 2024
- DUV Lasers Made with Nonlinear Crystals Enhance Lithography Performance
Apr 25, 2024
- Teledyne e2v, Airy3D Collaborate on 3D Vision Solutions
Apr 24, 2024